Propylparaben

Propylparaben

SCHEMBL1010568

CCCOC(=O)c1ccc(O)cc1.[CaH2]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.96
ALDH1A1 P00352 4/20 0.96
TSHR P16473 3/20 0.96
CHRM1 P11229 1/20 0.96
SLC6A2 P23975 1/20 0.96
KDR P35968 1/20 0.96
TDP1 Q9NUW8 1/20 0.96
LMNA P02545 4/20 0.77
SMN1; SMN2 Q16637 3/20 0.77
MAPK1 P28482 2/20 0.77
CYP1A2 P05177 2/20 0.77
CYP2C19 P33261 2/20 0.77
CYP2D6 P10635 1/20 0.77
NR1H2 P55055 1/20 0.77
RNASEL Q05823 1/20 0.77
ESR2 Q92731 2/20 0.69
CA12 O43570 2/20 0.69
CA1 P00915 2/20 0.69
CA2 P00918 2/20 0.69
CA7 P43166 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propylparaben SCHEMBL2812583 1.00 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL977 0.98 ESR1 (1.00) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL429594 0.98 ESR1 (1.00) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL9406450 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL31538674 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL5671589 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL31530539 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL1135822 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL8779117 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2
Propylparaben SCHEMBL6315856 0.96 ESR1 (0.96) ESR1ALDH1A1TSHRCHRM1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608929-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LyondellBasell Advanced Polymers Inc. (US) 2025-09-03 EP claimed
US-12338390-B2 Bridging particle and fluid loss control agent LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2025-06-24 US claimed
US-20240228859-A9 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-07-11 US claimed
WO-2024091462-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-05-02 WO claimed
US-20240132772-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-04-25 US claimed
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US claimed
US-20180077925-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2018-03-22 US claimed
EP-3265135-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF Wilson, John Paul (US) 2018-01-10 EP claimed
WO-2016144907-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2016-09-15 WO claimed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 EP claimed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 US claimed
EP-3592329-B1 USE OF COMPATIBLE SOLUTES SUSONITY Commercial GmbH (DE) 2026-02-18 EP disclosed
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent SYMRISE AG (DE) 2026-02-12 US disclosed
US-12545860-B2 Mannanase variants BASF SE (DE) 2026-02-10 US disclosed
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection SYMRISE AG (DE) 2026-02-05 US disclosed
WO-2004087740-A2 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORPORATION (US) 2004-10-14 WO disclosed
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto PROCYTE CORPORATION 2004-10-07 US disclosed
US-6800671-B1 UNSATURATED COMPOUND, ADHESION PROMOTER AND CURING AGENT; FLEXIBLE BIOADHESIVES BRITESMILE, INC. 2004-10-05 US disclosed
WO-2001081437-A1 LOW PEAK EXOTHERM CURABLE COMPOSITIONS BRITESMILE, INC. (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent TLR7, MYC, ERG28 ESR1 3004/4885ALDH1A1 4611/4885TSHR 1728/4885
US-12545860-B2 Mannanase variants MAN2A1, MANBA, IDUA ESR1 4832/4885ALDH1A1 4513/4885TSHR 3031/4885
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto AOC1, NONO, CUTA ESR1 978/4885ALDH1A1 340/4885TSHR 1460/4885
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection TYR, ERG28, CUTA ESR1 2772/4885ALDH1A1 1926/4885TSHR 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.